Wave Life Sciences Ltd. (WVE) NASDAQ
7.49
+0.17(+2.32%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
7.49
+0.17(+2.32%)
Currency In USD
| Previous Close | 7.32 |
| Open | 7.53 |
| Day High | 7.66 |
| Day Low | 7.25 |
| 52-Week High | 21.73 |
| 52-Week Low | 5.02 |
| Volume | 5.91M |
| Average Volume | 4.18M |
| Market Cap | 1.41B |
| PE | -6.19 |
| EPS | -1.21 |
| Moving Average 50 Days | 11.2 |
| Moving Average 200 Days | 10.22 |
| Change | 0.17 |
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
GlobeNewswire Inc.
Mar 05, 2026 1:30 PM GMT
Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWS
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 23, 2026 1:30 PM GMT
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno,
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 1:30 PM GMT
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conf